Regulatory approval

Published by the Health Service Executive. Approved

Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.

This is written in the approval document.

Reimbursement

Hospital

Citation

R-CEOP Therapy - 21 days, 2026, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6614/510_R-CEOP.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine